(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Wednesday and not separately reported by Alliance News: Read More
(Alliance News) - The following is a round-up of earnings for London-listed companies, issued on Wednesday and not separately reported by Alliance News: Read More
(Alliance News) - The following is a round-up of earnings and trading updates by London-listed companies, issued on Thursday and not separately reported by Alliance News: Read More
(Alliance News) - Arecor Therapeutics PLC on Monday highlighted the advancement of its lead product AT278, which is ultra-rapid-acting insulin, as it reported annual revenue growth. Read More
(Alliance News) - The following is a round-up of earnings for London-listed companies, issued on Thursday and not separately reported by Alliance News: Read More
(Alliance News) - The following is a round-up of earnings by London-listed companies, issued on Thursday and not separately reported by Alliance News: Read More
(Alliance News) - The following is a round-up of earnings by London-listed companies, issued on Thursday and not separately reported by Alliance News: Read More
(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Thursday and not separately reported by Alliance News: Read More
(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Monday and not separately reported by Alliance News: Read More
(Alliance News) - Arecor Therapeutics PLC on Monday said it has entered into a formulation development collaboration with California-based, clinical-stage biotechnology firm, Skye Bioscience Inc, as the pair seek to address the unmet needs in metabolic disease. Read More
(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Thursday and not separately reported by Alliance News: Read More
(Alliance News) - Arecor Therapeutics PLC on Tuesday reported a wider loss in 2024, despite an increase in revenue, as the company took a series of impairments related to its decision to refocus its efforts on its insulin candidate. Read More
(Alliance News) - Arecor Therapeutics PLC on Wednesday said it has partnered with an unnamed biopharmaceutical company to develop a novel formulation of peptide therapy. Read More
(Alliance News) - Arecor Therapeutics PLC on Monday said its revenue increased in 2024 and said it is excited by the prospects of its "superior insulin candidate". Read More
